Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer

SIMPLE SUMMARY: The survival of patients with metastatic colorectal cancer (mCRC) has been improved over the years and now reaches 30–40 months. However, few therapeutic options are available after failure of first- and second-line treatments. In fact, prognosis of chemo-refractory mCRC remains poor...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancers (Basel)
Autores principales: Ciardiello, Davide, Martini, Giulia, Famiglietti, Vincenzo, Napolitano, Stefania, De Falco, Vincenzo, Troiani, Teresa, Latiano, Tiziana Pia, Ros, Javier, Elez Fernandez, Elena, Vitiello, Pietro Paolo, Maiello, Evaristo, Ciardiello, Fortunato, Martinelli, Erika
Formato: Artigo
Lenguaje:Inglês
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC8073594/
https://ncbi.nlm.nih.gov/pubmed/33920531
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13081941
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares